For patients with resected pancreatic cancer who received neoadjuvant gemcitabine + Abraxane, would you switch to gemcitabine + capecitabine to complete 6 months of peri-operative therapy?

I would only administer neoadjuvant gem + Abraxane in very rare circumstances. If, for example, I have already tried mFFX and it did not achieve the response needed to get a borderline tumor to resectability. In that case, it would be tempting to use G+A as adjuvant therapy, but I would still strongly consider mFFX if the patient has adequate PS given the superior findings in the UNICANCER-PRODIGE 23 trial with that regimen.